Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CPIX's Cash to Debt is ranked higher than
91% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. CPIX: No Debt )
CPIX' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: No Debt

Equity to Asset 0.86
CPIX's Equity to Asset is ranked higher than
91% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. CPIX: 0.86 )
CPIX' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.91
Current: 0.86

0.42
0.91
F-Score: 6
Z-Score: 5.61
M-Score: -2.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 0.39
CPIX's Operating margin (%) is ranked higher than
60% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.59 vs. CPIX: 0.39 )
CPIX' s 10-Year Operating margin (%) Range
Min: -11.87   Max: 23.96
Current: 0.39

-11.87
23.96
Net-margin (%) 0.71
CPIX's Net-margin (%) is ranked higher than
61% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.31 vs. CPIX: 0.71 )
CPIX' s 10-Year Net-margin (%) Range
Min: -6.57   Max: 24.72
Current: 0.71

-6.57
24.72
ROE (%) 0.32
CPIX's ROE (%) is ranked higher than
61% of the 874 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. CPIX: 0.32 )
CPIX' s 10-Year ROE (%) Range
Min: -2.55   Max: 50.74
Current: 0.32

-2.55
50.74
ROA (%) 0.28
CPIX's ROA (%) is ranked higher than
63% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. CPIX: 0.28 )
CPIX' s 10-Year ROA (%) Range
Min: -2.26   Max: 24.03
Current: 0.28

-2.26
24.03
ROC (Joel Greenblatt) (%) 2.20
CPIX's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.17 vs. CPIX: 2.20 )
CPIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46.2   Max: 1632.74
Current: 2.2

-46.2
1632.74
Revenue Growth (%) -7.10
CPIX's Revenue Growth (%) is ranked higher than
56% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. CPIX: -7.10 )
CPIX' s 10-Year Revenue Growth (%) Range
Min: -7.1   Max: 47.5
Current: -7.1

-7.1
47.5
» CPIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CPIX Guru Trades in Q4 2013

John Rogers 2,538,760 sh (+44.33%)
Jim Simons 133,400 sh (-24.91%)
» More
Q1 2014

CPIX Guru Trades in Q1 2014

John Rogers 2,663,520 sh (+4.91%)
Jim Simons 95,597 sh (-28.34%)
» More
Q2 2014

CPIX Guru Trades in Q2 2014

John Rogers 2,663,170 sh (-0.01%)
Jim Simons 76,800 sh (-19.66%)
» More
Q3 2014

CPIX Guru Trades in Q3 2014

Jim Simons 84,100 sh (+9.51%)
John Rogers 2,607,251 sh (-2.1%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2013-12-31 Add 44.33%0.05%$4.59 - $5.17 $ 5.166%2538760
John Rogers 2013-09-30 Add 23.37%0.02%$4.44 - $5.76 $ 5.164%1758955
John Rogers 2013-06-30 Add 165.48%0.07%$4.56 - $5.35 $ 5.164%1425705
John Rogers 2013-03-31 New Buy0.05%$4.08 - $5.09 $ 5.1616%537021
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 303.50
CPIX's P/E(ttm) is ranked higher than
64% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.00 vs. CPIX: 303.50 )
CPIX' s 10-Year P/E(ttm) Range
Min: 12.4   Max: 303.53
Current: 303.5

12.4
303.53
P/B 1.10
CPIX's P/B is ranked higher than
93% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. CPIX: 1.10 )
CPIX' s 10-Year P/B Range
Min: 0.9   Max: 4.84
Current: 1.1

0.9
4.84
P/S 2.60
CPIX's P/S is ranked higher than
79% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. CPIX: 2.60 )
CPIX' s 10-Year P/S Range
Min: 1.65   Max: 6.82
Current: 2.6

1.65
6.82
EV-to-EBIT 248.48
CPIX's EV-to-EBIT is ranked higher than
65% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. CPIX: 248.48 )
CPIX' s 10-Year EV-to-EBIT Range
Min: -16.4   Max: 266.7
Current: 248.48

-16.4
266.7
Shiller P/E 30.70
CPIX's Shiller P/E is ranked higher than
85% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.40 vs. CPIX: 30.70 )
CPIX' s 10-Year Shiller P/E Range
Min: 16.32   Max: 35.82
Current: 30.7

16.32
35.82
Current Ratio 5.77
CPIX's Current Ratio is ranked higher than
89% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. CPIX: 5.77 )
CPIX' s 10-Year Current Ratio Range
Min: 1.45   Max: 14.46
Current: 5.77

1.45
14.46
Quick Ratio 5.27
CPIX's Quick Ratio is ranked higher than
88% of the 890 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. CPIX: 5.27 )
CPIX' s 10-Year Quick Ratio Range
Min: 1.38   Max: 13.46
Current: 5.27

1.38
13.46

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.20
CPIX's Price/Net Cash is ranked higher than
98% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPIX: 2.20 )
CPIX' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 6.72
Current: 2.2

1.37
6.72
Price/Net Current Asset Value 1.90
CPIX's Price/Net Current Asset Value is ranked higher than
98% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPIX: 1.90 )
CPIX' s 10-Year Price/Net Current Asset Value Range
Min: 1.21   Max: 5.93
Current: 1.9

1.21
5.93
Price/Tangible Book 1.50
CPIX's Price/Tangible Book is ranked higher than
92% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. CPIX: 1.50 )
CPIX' s 10-Year Price/Tangible Book Range
Min: 1.04   Max: 5.21
Current: 1.5

1.04
5.21
Price/DCF (Projected) 1.10
CPIX's Price/DCF (Projected) is ranked higher than
94% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.00 vs. CPIX: 1.10 )
CPIX' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 1.36
Current: 1.1

0.7
1.36
Price/Median PS Value 1.00
CPIX's Price/Median PS Value is ranked higher than
83% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. CPIX: 1.00 )
CPIX' s 10-Year Price/Median PS Value Range
Min: 0.66   Max: 2.54
Current: 1

0.66
2.54
Price/Graham Number 5.30
CPIX's Price/Graham Number is ranked higher than
72% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.77 vs. CPIX: 5.30 )
CPIX' s 10-Year Price/Graham Number Range
Min: 0.8   Max: 5.13
Current: 5.3

0.8
5.13
Earnings Yield (Greenblatt) 0.40
CPIX's Earnings Yield (Greenblatt) is ranked higher than
63% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. CPIX: 0.40 )
CPIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 76.6
Current: 0.4

0.4
76.6
Forward Rate of Return (Yacktman) 0.95
CPIX's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. CPIX: 0.95 )
CPIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.9   Max: 17.4
Current: 0.95

0.9
17.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CBJ.Germany
Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which they do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
CUMBERLAND PHARMACEUTICALS INC Financials Nov 15 2014
10-Q for Cumberland Pharmaceuticals, Inc. Nov 09 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 07 2014
Message From CEO Nov 04 2014
Cumberland Pharmaceuticals Reports Third Quarter 2014 Financial Results Nov 04 2014
Cumberland Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Nov 04 2014
Cumberland Pharmaceuticals Reports Third Quarter 2014 Financial Results Nov 04 2014
Q3 2014 Cumberland Pharmaceuticals Inc Earnings Release - After Market Close Nov 04 2014
Cumberland Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 4, 2014 Oct 21 2014
Cumberland Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 4, 2014 Oct 21 2014
Caldolor® Safely Treats Fever In Hospitalized Children Oct 14 2014
Caldolor® Safely Treats Fever In Hospitalized Children Oct 14 2014
Caldolor® Provides Favorable Inflammatory Response Results In Laparoscopic Cholecystectomy Surgery... Oct 10 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 08 2014
Cumberland Pharmaceuticals Reports Second Quarter 2014 Financial Results Aug 05 2014
Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 Jul 22 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 02 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition May 19 2014
Cumberland Pharmaceuticals' (CPIX) CEO A. J. Kazimi on Q1 2014 Results - Earnings Call Transcript May 13 2014
Cumberland Pharmaceuticals Reports First Quarter 2014 Financial Results May 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK